The potentiating effect of sertraline and fluoxetine on amphetamine- induced locomotor activity is not mediated by serotonin

Psychopharmacology

Volumn 143, Issue 4, 1999, Pages 426-432

  Sills, T L ^a   Greenshaw, A J ^b   Baker, G B ^b   Fletcher, P J ^a  

^a Clarke Division   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

5,7 Dihydroxytryptamine; 5 Hydroxytryptamine; Cytochrome P450; Dorsal raphe; Median raphe; SSRI; Wistar rat

Indexed keywords

AMPHETAMINE; FLUOXETINE; SERTRALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUOXETINE; LOCOMOTION; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0032935826     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050968     Document Type: Article

References (33)

1. Al-Dabbagh SG, Idle JR, Smith RL (1981) Animal modeling of human polymorphic drug oxidation: the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 33:1616-164
2. Arnt J, Hyttel J, Overo KF (1984) Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions. Pol J Pharmacol Pharm 36:221-230
3. Benet LZ, Kroetz DL, Sheiner LB (1996) Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (eds) Goodman and Gilman's the pharmacological basis of therapeutics, ninth edition. McGraw-Hill, New York, pp 3-27
4. Ceci A, Baschirotto A, Borsini F (1993) Effect of fluoxetine on the spontaneous electrical activity of fronto-cortical neurons. Eur J Pharmacol 250:461-464
5. 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Brit J Pharmacol 92:881-894
6. Creasey WA (1979) Drug disposition in humans, the basis of clinical pharmacology. Oxford University Press, New York
7. DeVane CL (1979) Fundamentals of monitoring psychoactive drug therapy. Williams and Wilkins, Baltimore
8. Dugast C, Suaud-Chagny MF, Gonon F (1994) Continuous in vivo monitoring of evoked dopamine release in the rat nucleus accumbens by amperometry. Neuroscience 62:647-654
9. Fischer JF, Cho AK (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208:203-209
10. Hascoet M, Bourin M, Payeur R, Lombet A, Peglion JL (1995) Sigma ligand S14905 and locomotor activity in mice. Eur Neuropsychopharmacol 5:481-489
11. 2receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol 238:291-296
12. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9:19-26
13. Lane RM (1996) Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 11:31-61
14. Law MYL, Moody DE (1994) Urinary excretion of amphetamine and 4-hydroxyamphetamine by Sprague-Dawley and Dark Agouti rats. Life Sci 54:1073-1079
15. Layer RT, Uretsky NJ, Wallace LJ (1992) Effect of serotonergic agonists in the nucleus accumbens on d-amphetamine-stimulated locomotion. Life Sci 50:813-820
16. Leccese AP, Lyness WH (1984) The effects of putative 5-hydroxytryptamine receptor active agents on D-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions. Brain Res 303: 153-162
17. Maj J, Rogoz Z, Skuza G, Sowinska (1984) Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine. J Pharm Pharmacol 36:127-130
18. Maj J, Rogoz Z, Skuza G (1996) Some behavioral effects of 1,3-di-o-tolylguanidine, opipramol and sertraline, the sigma site ligands. Pol J Pharmacol 48:379-395
19. Matsumoto M, Yoshioka M, Togashi H, Tochihara M, Ikeda T, Saito H (1995) Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther 272:1044-1051
20. Moody DE, Ruangyuttikarn W, Law MY (1990) Quinidine inhibits in vivo metabolism of amphetamine in rats: impact upon correlation between GC/MS and immunoassay findings in rat urine. J Anal Toxicol 14:311-317
21. Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307:117-119
22. Nemeroff CB, DeVane CL, Pollock BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320
23. 3mediated control of dopaminergic function. Psychopharmacology 112:860-867
24. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, Sydney
25. Prisco S, Esposito E (1995) Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol 116:1923-1931
26. Raiteri M, Cerrito F, Cervoni AM, Levi G (1979) Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther 208:195-202
27. Richelson E (1997) Pharmacokinetic drug interactions of new antidepressants: a review of the effects of on the metabolism of other drugs. Mayo Clin Proc 72:835-847
28. Riesenman C (1995) Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 15:84S-99S
29. Rotzinger S, Todd KG, Bourin M, Coutts RT, Baker GB (1997) A rapid electron-capture gas chromatographic method for the quantification of fluvoxamine in Brain tissue. J Pharmacol Toxicol Meth 37:129-133
30. Shen WW (1997) The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. Biol Psychiatry 41:814-826
31. Sills TL, Greenshaw AJ, Baker GB, Fletcher PS (1999) Acute Fluoxetine treatment potentiates amphetamine-hyperactivity and amphetamine-induced accumbens-dopamine release: possible pharmacokinetic interaction. Psychopharmacology 141: 421-427
32. Skuza G, Rogoz Z, Wieczorek A (1997) Neuropsychopharmacological profile of remoxipride in comparison with clozapine. Pol J Pharmacol 49:5-15
33. Tomkins DM, Otton SV, Joharchi N, Berns T, Wu D, Corrigall WA, Sellers EM (1997) Effect of CYP2D1 inhibition of the behavioural effects of d-amphetamine. Behav Pharmacol 8:223-235